FusionVAC22_01: a phase I clinical trial evaluating a DNAJB1-PRKACA fusion transcript-based peptide vaccine combined with immune checkpoint inhibition for fibrolamellar hepatocellular carcinoma and…

Overview of attention for article published in Frontiers in oncology, March 2024

Altmetric Badge

Mentioned by

twitter: 2 X users

Readers on

mendeley: 2 Mendeley

So far, Altmetric has seen 2 X posts from 2 X users, with an upper bound of 18,657 followers.

RT @FrontOncology: New research: FusionVAC22_01: a phase I clinical trial evaluating a DNAJB1-PRKACA fusion transcript-based peptide vaccin…

29 Mar 2024

Reply Repost Favourite

New research: FusionVAC22_01: a phase I clinical trial evaluating a DNAJB1-PRKACA fusion transcript-based peptide vaccine combined with immune checkpoint inhibition for fibrolamellar hepatocellular carcinoma and other tumor entities carrying… https://t.co/

29 Mar 2024

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.